Management Options in Triple-Negative Breast Cancer
نویسندگان
چکیده
منابع مشابه
Management Options in Triple-Negative Breast Cancer
Notorious for its poor prognosis and aggressive nature, triple-negative breast cancer (TNBC) is a heterogeneous disease entity. The nature of its biological specificity, which is similar to basal-like cancers, tumors arising in BRCA1 mutation carriers, and claudin-low cancers, is currently being explored in hopes of finding the targets for novel biologics and chemotherapeutic agents. In this re...
متن کاملTriple-Negative Breast Cancer: Adjuvant Therapeutic Options
Triple-negative breast cancer (TNBC), a subtype distinguished by negative immunohistochemical assays for expression of the estrogen and progesterone receptors (ER/PR) and human epidermal growth factor receptor-2(HER2) represents 15% of all breast cancers. Patients with TNBC generally experience a more aggressive clinical course with increased risk of disease progression and poorer overall survi...
متن کاملManagement of triple negative breast cancer.
Triple negative breast cancer (TNBC) accounts for approximately 15% of breast cancer cases. TNBC is an immunohistochemically defined subtype, with significant diversity within the subtype. Generally TNBC occurs in younger women and is marked by high rates of relapse, visceral and CNS metastases, and early death. Current therapy fails to curtail the innate aggressive behaviour of TNBC in the maj...
متن کاملTriple-Negative Breast Cancer: Frequency, Molecular Subtypes, and Therapeutic Options
INT RO DUC TI ON Breast cancer is the most common malignancy in women. An estimated 1 million cases of breast cancer are diagnosed annually worldwide and 400.000 patients die from the disease every year[1]. Multiple oncogenes, tumor suppressor genes, and sex steroid hormones and their receptors are involved in the genesis and development of breast cancer. Breast cancer is a heterogeneous malign...
متن کاملTreatment options for patients with triple-negative breast cancer
Breast cancer is a heterogeneous disease composed of different subtypes, characterized by their different clinicopathological characteristics, prognoses and responses to treatment. In the past decade, significant advances have been made in the treatment of breast cancer sensitive to hormonal treatments, as well as in patients whose malignant cells overexpress or amplify HER2. In contrast, mainl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Breast Cancer: Basic and Clinical Research
سال: 2011
ISSN: 1178-2234,1178-2234
DOI: 10.4137/bcbcr.s6562